Take the e-learning and claim your CME credit. Watch the video and download the slides.

E-learning: Current opinions on managing nmCRPC and the implications of new imaging modalities

Following on from the success of the Experts Knowledge Share meeting, GU CONNECT has produced an interactive e-learning, slide set and video.

GUI CONNECT members, Prof. Alicia Morgans (USA) and Prof. David Pfister (Germany), along with guest expert Prof. Alexander Drzezga (Germany) provide an overview of next-generation imaging modalities and consider the potential impact of findings on treatment options for non-metastatic castration-resistant prostate cancer.Two alternative approaches are presented:

  • Delay time to systemic therapy
  • Use systemic medications sooner

Take the e-learning and claim your CME credit.

Watch the video and download the slides.

The e-learning is accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) whose system of credits are recognised by AMA and the Royal College of Physicians and Surgeons of Canada.

Hi, my name is Alex Drzezga. I’m the chair of the Department of Nuclear Medicine, at the University of Cologne in Germany.


I had the pleasure to contribute to a virtual GU CONNECT Expert Knowledge Share. This session was focused on the somewhat controversial topic of the so-called non-metastatic castration-resistant prostate cancer, and the main aim of the session was to discuss the added value of modern imaging tools, particularly PSMA-PET on selecting treatment options for nmCRPC patients.


This particularly referred to the choice between selecting localised therapy approaches with the potential to delay systemic therapy, versus directly forwarding patients to systemic medications.


In that session, I myself presented a lecture on the added value of molecular imaging and prostate cancer in different clinical situations, including nmCRPC, which in fact shows metastasis in a number of cases on PSMA-PET.


Next, the case study was presented which was then discussed by the distinguished experts' Professor Alicia Morgans and Professor David Pfister with regard to delaying systemic therapy or starting it earlier.


Subsequently, we went into several breakout groups supported by the additional experts' Professor Gert Attard and Professor Neal Shore and joined by participants from all over the world. This resulted in a most lively discussion on the topic.


I think this was a really great session and I wish to thank all the attendees and the experts.


We’d like to invite you now to have a look at the provided slide decks, to learn more about this really important topic.


David Pfister


Hello my name is David Pfister, I’m a Deputy Chairman of the Urological Department of the University of Cologne.


We are doing both medical treatment and surgery in all oncologic patients. So I was very pleased to be part of the Expert Knowledge Share programme of the GU CONNECT group, to discuss castrate-resistant prostate cancer in the non-metastatic disease.


We had a very nice introduction from Professor Drzezga showing us the value of PSMA-PET in this setting, and finally, I showed how, probably, metastasis directed treatment can work out, and finally Alicia Morgans discussed with us the medical treatment in M0 CRPC patients.


Finally, I hope you will enjoy the discussion which was recorded during the meeting and please do not miss to take the e-learning to get your credit points, thank you very much.


Alicia Morgans


Hi my name is Alicia Morgans and I’m a GU Medical Oncologist and Associate Professor of Medicine at Northwestern University in Chicago in the United States.


I was so pleased to participate in the GU CONNECT Expert Knowledge Share in which we discussed imaging controversies and considered whether or not non-metastatic castration-resistant prostate cancer truly exists.


In this conversation, we discussed opportunities for metastasis-directed therapy and potentially preventing systemic therapy or delaying it.


However, I presented that my take was that systemic intensification was truly necessary because patients have not only a longer metastasis-free survival, but a better quality of life and even an overall survival improvement with intensification of AR antagonist therapy in addition to ADT, in the setting of patients having non-metastatic CRPC.


Of course we also discussed how imaging really confounds the issue, and when we cannot see evidence of disease on conventional bone scans and CT scans, but we can see evidence of disease in PSMA or axumin PET scans, we sometimes don’t know what to do. However, patients who had PSMA positive disease but negative conventional imaging were actually included in the studies that led to the approval of the AR antagonist therapies in the non-metastatic CRPC setting and of course gave us our level one, category one evidence to suggest that intensification was the way to go.


Please participate in the e-learning and watch our videos, let us know what you think and please complete the survey at the end, we really appreciate your participation.

After finishing medical school in November 2004 Dr Pfister started his residency in the Department of Urology at the University of Cologne. For his endoscopic training, he switched to the General Hospital in Weiden (Oberpfalz/Bavaria) between August 2006 and March 2007. After returning to Cologne Dr Pfister heightened my oncologic education under Prof. Heidenreich. The oncologic training consisted of two arms: medical and surgical oncology. In 2009 his education was augmented at the University Hospital of Aachen. In 2010 he passed his urologic board exam. Since 2011 Dr Pfister has been working as a staff urologist with main interests in castration-resistant prostate cancer and testicular cancer. In 2011 he passed the Charles Huggins grant, an educational grant at the Center for Prostate Disease Research in Maryland, USA. In 2012 Dr Pfister received an additional qualification in the systemic treatment of solid tumours and since that time he has organised and led the urological clinical trial centre. In 2012 Dr Pfister qualified as a Professor and became an Associate Professor in November 2012 for medical oncologic treatment in urological tumours. At the end of 2015 he became the Commissionary Leader of the Urologic Department of the University of Aachen. Since 2016 Dr Pfister has become the Deputy Director of the Department of Urology, Uro-oncology and Robot-Assisted Surgery, University Hospital of Cologne. Special interest is castration-resistant, radiation-resistant prostate cancer and testicular cancer.

Prof. David Pfister has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Bayer, Merck, MSD, Janssen and Pfizer. 

Dr Morgans is Genitourinary Medical Oncologist at Dana-Farber Cancer Institute, and Faculty in Medicine at Harvard Medical School in Boston, MA. She completed medical school and residency at the University of Pennsylvania School of Medicine, fellowship in Hematology/Oncology at Harvard’s Dana Farber Cancer Institute and Massachusetts General Hospital Cancer Center in Boston and earned a Master of Public Health at Vanderbilt University. Dr Morgans treats patients with prostate, bladder, and testicular cancer, and her research assesses complications of advanced prostate cancer survivorship and patient-centered treatment decision-making in advanced prostate cancer.

Assoc. Prof. Alicia Morgans has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AAA, Astellas, AstraZeneca, Bayer, Exelixis, Janssen, Myovant, Novartis, Pfizer, Sanofi and Telix. 

Programme summary
Take the e-learning now
Share this programme
This educational programme is supported by an Independent Medical Education Grant from Bayer
This course has been accredited by EACCME® for ECMEC®.
I agree that this educational programme:

Was valuable to me

Brought to you by

GU CONNECT is an initiative of COR2ED, supported by Independent Educational Medical Grants from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts

Other programmes of interest

The evolving role of liquid biopsy in biomarker testing

Clinical application of liquid biopsy, and how it applies to NSCLC, breast and colorectal cancer

Assoc. Prof. Umberto Malapelle
  • download Downloadable
  • clock 5 MIN
  • calendar Jul 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Interactive patient case
Advanced renal cell carcinoma: Managing a long-term durable response

Maximising outcomes for patients with advanced RCC 

Prof. Michael Staehler
Endorsed by
Urobel VZW | ASBL
  • clock 15 MIN
  • calendar Jun 2024

Educational programme supported by an Independent Medical Education grant from Eisai Europe Limited.



of 1

Overcoming pre-analytical phase challenges in gastric, prostate and lung cancer

Medical experts make recommendations for best practice

Dr Alexander Wyatt, Prof. Frédéric Bibeau
Endorsed by
  • download Downloadable
  • clock 5 MIN
  • calendar Jun 2024

Educational programme supported by an Independent Medical Education grant from AstraZeneca and Amoy Diagnostics.
Conference update
Oncogene-addicted NSCLC: Highlights from ASCO 2024

The latest non-small cell lung cancer data presented at ASCO

Prof. Nicolas Girard
  • download Downloadable
  • clock 3 MIN
  • calendar Jun 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Upper lower GI cancer update ASCO 2024 Conference update
Upper and lower GI cancer update from ASCO 2024

GI oncologists review the latest data presented at ASCO 2024

Dr Samuel J Klempner, Dr Elizabeth Smyth, Prof. Jenny Seligmann, Dr Dominik Modest
  • clock 8 MIN
  • calendar Jun 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Experts Knowledge Share Video
Oncology Hemato-oncology 
Optimising the management of multiple myeloma in the early relapsed/refractory setting (RRMM)

Medical experts discuss the latest learnings from clinical practice

Prof. Aurore Perrot, Prof. Hermann Einsele, Assoc. Prof. Karthik Ramasamy, Assoc. Prof. Joshua Richter
  • download Downloadable
  • clock 76 MIN
  • calendar Jun 2024

Educational programme supported by an Independent Medical Education grant from Menarini Stemline Oncology.